o This study looked at the potential effects of a concomitant smoking cessation program in patients currently addicted to cocaine and/or methamphetamine. o Hypothesis: Concurrent treatments for substance use disorder and smoking cessation will improve stimulant-use outcomes.
o Randomized, two group study, not blinded o In a 1:1 ratio patients were either selected to a smoking cessation treatment program in addition to their substance abuse disorder treatment, or receive substance abuse disorder treatment alone ("treatment as usual") o Duration: 10 weeks, with follow-ups at 3 and 6 months o Inclusion Criteria:
o Enrolled in outpatient substance use disorder treatment o Interested in quitting smoking. o Primary-Weekly proportion of stimulant-abstinent participants during the treatment phase  Assessed by stimulant-negative urine drug screen and self-report of no stimulant use. o Secondary  Proportion of stimulant-abstinent participants at follow-up  Proportion of drug-abstinent participants during active treatment and follow-up  Stimulant-free and drug-free days during the active treatment phase and followup  Smoking point-prevalence abstinence at the end of treatment and follow-up  Substance use disorder treatment attendance during the active treatment phase o Data Handling-Intent to treat (All 538 patients included in safety and efficacy analysis)
Results:
o 89% (n=479) of participants completed the 10-week active treatment period; 85% completed the 3-month follow-up; 79.6% (n=428) completed the 6-month follow-up o Approximately 93% of the bupropion pills were taken (92% self-report; 94% pill count) o Only approximately 6% of patients used the NICOTROL inhaler as directed (at least 6 times daily) o 73% of patients receiving the smoking cessation regimen reported at least 1 adverse event compared to 58% in the treatment as usual group. o 48% of patients in the smoking cessation group reported an AE due to a study medication. o 13 patients (5%) discontinued the study due to bupropion complications; 7 patients (2.6%) discontinued due to Nicotrol-related AE's o Insomnia, anxiety, nausea, dry mouth, headache, and throat irritation were all AE's that were reported in over 5% of smoking cessation patients and were statistically significant when compared to the treatment as usual group. o There was no difference in groups in terms of serious AE's. o Author's Conclusions:
o Hypothesis of providing smoking cessation treatment in addition to substance use disorder treatment would improve stimulant-use outcomes was rejected. o There was no significant treatment effects for drug abstinence but that participants receiving smoking-cessation treatment may experience better outcomes for drug-free days. o Substance use disorder treatment attendance did not differ between the participants receiving smoking-cessation treatment and those only receiving substance use disorder.  This differs from a previous student suggesting a decrease in attendance with smoking cessation treatment o Results suggest that smoking-cessation treatment significantly improved smokingabstinence outcomes for stimulant-dependent  Indicated by the odds ratio of 18.23 for smoking-cessation treatment, compared to treatment as usual, for end-of-treatment point-prevalence abstinence rate 
Conclusions:
o Providing concurrent smoking cessation programs to these patients' substance use disorder treatment improves smoking outcomes, in particular, smoking abstinence o Numerous non-serious adverse effects are associated with smoking cessation treatment discontinuation and limit the usefulness of the program in stimulant-dependent patients. o Monetary rewards, as well as drug and tobacco use screening regimens/techniques, limit the generalizability of the study's results. o I would have liked to have seen urine cotinine testing rather than CO monitoring o Patients are likely more willing to report not smoking, given the chance of a reward o I would have liked to have seen different tobacco cassation regimens used (e.g. bupropion alone, nicotine patch, nicotine gum) o Other regimens may be associated with less adverse effects, leading to a higher adherence rate, and easier statistical analysis.
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